Effects of Allium victorialis leaf extracts and its single compounds on aldose reductase, advanced glycation end products and TGF-β1 expression in mesangial cells

Young Sook Kim¹, Dong Ho Jung¹, Ik Soo Lee¹, So-Jin Choi¹, Song Yi Yu¹, Sea-Kwang Ku², Myung-Hwa Kim³,⁴ and Jin Sook Kim¹*

Abstract

Background: Accumulating evidences suggest that aldose reductase (AR) inhibitors and advanced glycation end product (AGE) formation inhibitors may prevent chronic hyperglycemia-induced long-term complication in diabetes. Transforming growth factor-beta1 (TGF-β1) plays an important role in the development of diabetic nephropathy. Allium species have been utilized in folk medicine throughout the world for the treatment of various physical disorders. However, the benefits of Allium victorialis (A. victorialis) against diabetic complications, especially nephropathy, have yet to be explored. In the present study, we investigated the protective effect of the compounds isolated from A. victorialis leaf on diabetic nephropathy.

Methods: In vitro AR activity, AGEs formation, and AGE-receptor for AGES (RAGE) binding in human RAGE (hRAGE)-overexpressing cells were tested. High glucose-induced transforming growth factor-beta1 (TGF-β1) expression was also examined in mouse kidney mesangial cells (MMCs) cultured under high glucose.

Results: Of the isolated eight compounds from A. victorialis leaf extracts tested, quercitrin exhibited the most pronounced inhibitory effects on AR activity (IC₅₀ value of 0.17 μM) and AGEs formation (IC₅₀ value of 4.20 μM). Furthermore, quercitrin disrupted AGE-RAGE binding in a concentration-dependent manner in hRAGE-overexpressing cells. Additionally, of the eight compounds tested, ferulic acid significantly reduced high glucose-induced TGF-β1 expression and secretion in MMCs.

Conclusions: Our results suggest that active compounds isolated from A. victorialis leaf exhibit inhibitory effects on AR activity in rat lenses and AGE formation. Further, ferulic acid reduces TGF-β1 mRNA expression and secretion in MMCs under diabetic conditions. Thus, A. victorialis is a good candidate for the development of treatments for diabetic nephropathy.

Keywords: Allium victorialis, Aldose reductase, Advanced glycation end products, Diabetic nephropathy, transforming growth factor-beta1, Mouse mesangial cells
Background
Chronic hyperglycemia is the most common feature of all forms of diabetes mellitus, and it accelerates the induction of aldose reductase (AR, EC 1.1.1.21) and the irreversible formation of advanced glycation end products (AGEs), which play important roles in the pathogenesis of diabetic complications [1]. Diabetic nephropathy is a major complication of diabetes mellitus, and although the mechanism of glomerulosclerosis still remains unclear, the irreversible formation of AGEs, polyol accumulation, and oxidative stress have been considered the major causes of diabetic nephropathy [2]. AR, the first rate-limiting enzyme in the polyol pathway, is present in the eyes, kidneys, and other tissues affected by diabetic complications. Increased glucose enters the polyol pathway, where it is reduced by AR to sorbitol [2,3]. AR inhibitors (ARIs), such as epalrestat, 3,3-tetramethyleneglutaric acid (TMG), and fidarestat, have been developed, and some have been revealed to prevent diabetic nephropathy in animal models or patients [3-7]. ARIs from natural products have been found to prevent or delay the development of diabetic complications in animal models [8-10].

Transforming growth factor-beta 1 (TGF-β1) is a multifunctional cytokine that plays important roles in cell proliferation, wound healing, differentiation, apoptosis, and the immune response in several cells [11]. In particular, TGF-β1 is a key mediator of diabetic nephropathy that increases the levels of extracellular matrix (ECM) proteins, such as collagen I and IV, laminin, and fibronectin, in the glomeruli [11]. In addition, TGF-β has been identified as a critical regulator and mediator of pathophysiological processes of ocular tissue development or repair. TGF-β–mediated signaling is involved in the progression of diabetic nephropathy, and high levels of TGF-β are found in diabetic kidneys.

Natural products and their active constituents have been reportedly used for the treatment of diabetes and diabetic complications [10]. The genus Allium comprises more than 600 different species distributed throughout North America, North Africa, Europe, and Asia. Many Allium species have been utilized in folk medicine throughout the world for the treatment of various physical disorders such as burns, wounds, headaches, chest colds, and rheumatism [12]. Allium victorialis var. platyphyllum (Liliaceae), one of the most popular Allium species, is an edible perennial herb widely distributed on Ulleung Island and Mt. Hambeak of the Korean Peninsula. Recently, Allium victorialis (A. victorialis) has received much attention owing to its diverse and potentially significant pharmacological properties including antiarteriosclerotic, anticancer, antioxidant, anti diabetic, antiobesity, antineuroinflammatory, hepatoprotective, and nephroprotective effects [12-21].

In this paper, we examined the effects of eight compounds (1–8) isolated from A. victorialis leaf on AR activity, AGE formation, and TGF-β1 mRNA expression and protein secretion in mouse glomerular mesangial cells (MMCs) cultured under diabetic conditions. Furthermore, binding between AGE and receptor for AGE (RAGE) in human RAGE (hRAGE)-overexpressing MMCs was analyzed, and the most active compound was identified. These results show that single compounds from A. victorialis leaf extracts have preventive effects against diabetic nephropathy and may be useful as candidates for preclinical study in the treatment of diabetic nephropathy.

Methods
Plant materials and chemicals
The leaf of A. victorialis were purchased from a commercial supplier in Goryung, (Gyeongbuk, Korea, in January, 2005) and identified by Prof. K-R Park in the Department of Herbology, The Medical Research center for Globalization of Herbal Formulation, Daegu Haany University. A herbarium voucher specimen (no. KIOM-ALVI) has been deposited at the Herbarium of the Diabetic Complications Research Group, Korea Institute of Oriental Medicine. Antibodies were purchased from Cell Signaling (Beverly, MA) and Santa Cruz Biotechnology (Santa Cruz, CA). All other reagents were obtained from Sigma-Aldrich (St. Louis, MO). Reagents used for cell culture were purchased from GIBCO-BRL (Grand Island, NY).

General experimental procedures
Optical rotations were measured on a JASCO P-2000 digital polarimeter. Hydrogen 1 (300 MHz) and carbon 13 nuclear magnetic resonance (NMR; 75 MHz) spectra were obtained using a Bruker DRX-300 spectrometer with tetramethylsilane as an internal standard. Two-dimensional-NMR experiments (correlation spectroscopy, heteronuclear multiple-quantum correlation, and heteronuclear multiple bond correlation) were run on a Bruker Avance 500 NMR spectrometer. Electrospray ionization mass spectrometry spectra were recorded on a Shimadzu liquid chromatography–mass spectrometry-trap-time of flight spectrometer. Column chromatography was performed using silica gel (70–230 mesh, Merck), YMC-gel ODS-A (12 nm, S-75 μm, YMC), and Sephadex LH-20 (Amersham Pharmacia Biotech). Thin-layer chromatography was performed on pre-coated silica gel 60 F254 (0.25 mm, Merck) and RP-18 F254a plates (0.25 mm, Merck). Spots were detected by ultraviolet light (254 nm) and spraying with 10% H2SO4 followed by heating.
Extraction and isolation

The air-dried leaf of *A. victorialis* (4.0 kg) were extracted with 50% EtOH (36 L) at 60°C for 5 h, filtered, and concentrated to yield a 50% EtOH extract (1.0 kg). This extract (1.0 kg) was suspended in H2O (4 L) and then partitioned successively with EtOAc (3 × 4.0 L) and n-BuOH (3 × 4.0 L) to afford EtOAc- (13 g) and n-BuOH-soluble fractions (258 g), respectively. The EtOAc- (12 g) and n-BuOH-soluble fractions (250 g) were subjected to a series of chromatographic techniques including silica gel, YMC RP-18, and Sephadex LH-20 column chromatographies, leading to the isolation of eight compounds (1–8, Table 1), Kaempferol 3,7,4'-O-β-D-triglucopyranoside (1, 280 mg), Kaempferol 3,7-O-β-D-diglucopyranoside (2, 66 mg), kaempferol 3,4'-O-β-D-diglucopyranoside (3, 70 mg), quercitrin (4, 10 mg), kaempferol (5, 24 mg), quercetin (6, 45 mg), 4-hydroxycinnamic acid (7, 4.3 mg), and ferulic acid (8, 10 mg).

Rat lens AR activity

AR activity was measured as described previously [9,22]. All animal procedures were approved by the Korea Institute of Oriental Medicine Institutional Animal Care Committee on animal care at our institute and conducted according to institutional guidelines. Rat lenses were isolated from the eyes of 8-week-old Sprague–Dawley rats (Orient Co., Seongnam, Korea) and homogenized in 12 volumes of 150 mM sodium phosphate buffer (pH 6.2) and 10 mM 2-mercaptoethanol. The homogenate was centrifuged at 14,000 rpm for 30 min, and the supernatant was used as crude rat lens AR. The incubation mixture contained 150 mM sodium phosphate buffer, 0.15 mM nicotinamide adenine dinucleotide phosphate (NADPH), 10 mM DL-glyceraldehyde as a substrate, and 700 μM of enzyme substrate, with or without compounds or positive control, in a total volume of 1.0 ml. The reaction was initiated by the addition of NADPH at 37°C and stopped by the addition of 0.15 ml of 0.5 N HCl. Next, 0.5 ml of 6 M NaOH containing 10 mM imidazole was added, and the solution was heated at 60°C for 15 min to convert NADP to a fluorescent product. The fluorescence (ex. 360 nm/ em. 460 nm) was assayed using a spectrofluorometric detector (Synergy HT, Bio-Tek, Winooski, VT). The concentration of each test sample that inhibited activity by 50% (IC50) was estimated from the least-squares regression line of the logarithmic concentration plotted against the remaining activity.

**Table 1 Inhibitory effect of extracts, fractions, and compounds isolated from *A. victorialis* on AR and AGEs formation**

| No. | Extracts, fractions, and isolated compounds | Mw | AR IC50 | AGEs IC50 |
|-----|-------------------------------------------|----|---------|-----------|
| 1   | Kaempferol 3,7,4'-O-β-D-triglucopyranoside | 772.66 | >50 μM | >100 μM |
| 2   | Kaempferol 3,7-O-β-D-diglucopyranoside     | 610.52 | >50 μM | 56.4±1.39 μM |
| 3   | Kaempferol 3,4'-O-β-D-diglucopyranoside    | 610.52 | 9.77±0.33 μM | 59.6±1.22 μM |
| 4   | Quercitrin                                 | 448.38 | 0.17±0.10 μM | 4.20±0.04 μM |
| 5   | Kaempferol                                 | 286.24 | 1.10±0.03 μM | 36.0±1.40 μM |
| 6   | Quercetin                                  | 302.24 | 3.61±0.19 μM | 27.1±0.11 μM |
| 7   | 4-Hydroxycinnamic acid                     | 164.16 | >50 μM | 9.9±0.11 μM |
| 8   | Ferulic acid                               | 194.16 | >50 μM | 7.5±0.20 μM |
| 9   | A. victorialis 50% EtOH                    | >10 μg/ml | >75 μg/ml |
| 10  | A. victorialis EtOAc                       | 7.53±0.02 μg/ml | 30.1±1.68 μg/ml |
| 11  | A. victorialis BuOH                        | >10 μg/ml | >75 μg/ml |
| 12  | Tetramethylenegluutaric acid               | 186.20 | 5.07±0.06 μM (0.94±0.01 μg/ml) | - |
| 13  | Aminoguanidine                             | 74.1 | - | 1.03±0.07 mM (76.47±4.81 μg/ml) |

**Determination of AGEs formation**

AGEs formation assay was performed as previously described [23,24]. Bovine serum albumin (BSA, 10 mg/ml, Sigma-Aldrich) in 50mM phosphate buffer (pH 7.4) with containing 0.02% sodium azide to prevent bacterial growth was added to 0.2 M fructose and glucose. The reaction mixture was then mixed with compounds or aminoguanidine (AG, Sigma-Aldrich). After incubating at 37°C for 7 days, the fluorescent reaction products were assayed on a spectrofluorometric detector (BIO-TEK, Synergy HT, Ex: 350 nm/Em: 450 nm). AGEs assay was performed in quadruplicate. The concentration of each test sample giving 50% inhibition of the activities (IC50) was estimated from the least-squares regression line of the logarithmic concentration plotted against the remaining activity.

**Cell Cultures**

Mouse kidney mesangial cells (SV40 MES13, MMC) were obtained from the American Type Culture Collection (#CRL-1927, Rockville, MD) and cultured in Dulbecco’s modified Eagle’s medium:F-12 (3:1) supplemented with 14
mM HEPES, penicillin 100 U/ml, streptomycin 100 μg/ml, and 5% fetal bovine serum. Cells were routinely grown to confluence in a humidified 37°C, 5% CO2 incubator.

**RNA extraction and semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR) analysis**

Total cellular RNA was extracted with TRIzol (Invitrogen, Carlsbad, CA), quantified by measuring the absorbance at 260 nm, and stored at −80°C until analysis. The expression of TGF-β1 and GAPDH mRNAs was detected by RT-PCR analysis. The extracted RNA (1 μg) was subjected to a reverse transcriptase reaction with the Maxime RT premix (Intron, Daejeon, Korea) at 42°C for 60 min and 72°C for 10 min. Subsequently, semi-quantitative PCR was performed with Accupower® PCR premix (Intron, Daejeon, Korea). The primer sequences were as follows: mouse TGF-β1 (sense) 5'-TGA ACC AAG GAG ACG GAA TAC AGG -3' (anti-sense) 5'-GCC ATG AGG AGC AGG AAG GG -3' and mouse GAPDH (sense) 5'-GCC ATG AGG AGC AGG AAG GG -3' (anti-sense) 5'-ACG GCA AAT TCA ACG CAG CAG -3'. Aliquots of PCR products were electrophoresed on 1.2% agarose gels and visualized after ethidium bromide staining.

**Detection of secreted TGF-β1 expression in MMCs using enzyme-linked immunosorbent assay (ELISA)**

The levels of TGF-β1 in the medium were determined as described previously [9]. The medium was replaced with serum-free medium containing compound under high glucose conditions for 24 h. This medium was then harvested and TGF-β1 was activated by treatment with 1 N HCl (0.1 ml/0.5 ml of conditioned media) for 10 min at room temperature, then 0.1 ml 1.2 N NaOH/0.5 M HEPES was added. Quantikine mouse TGF-β1 ELISA (R&D systems, Minneapolis, MN) was performed according to the manufacturer’s protocol, and the TGF-β1 levels were normalized to those of total protein. Medium without cells that had been incubated under the same conditions was used as a control for the ELISA.

**Detection of live cell-based AGE-BSA/RAGE binding**

AGE-BSA/RAGE binding in the cells was determined as described previously [23]. Briefly, Alexa 488 labeling of AGE-BSA was performed using the Alexa Fluor® 488 protein labeling kit (Molecular Probes, Eugene, OR). For the binding assay, human RAGE-overexpressing cells (1×10^4) were seeded onto a 96-well assay plate with a clear bottom lid and black plate (Corning, NY) and incubated with serum-free media for 24 h. Before binding, 3% BSA was added for 30 min to block non-specific binding. Cells were treated with 5 μg of Alexa Fluor 488-labeled AGE-BSA in a total volume of 100 μl serum-free medium and incubated in the dark for 6 h in a 5% CO2 humidified atmosphere at 37°C. Compounds were added after the addition of AGES-BSA-Alexa Fluor 488 to hRAGE-overexpressing cells. The non-specific binding of AGE-BSA-Alexa Fluor 488 to cell surface proteins other than hRAGE was compared by incubating cells with untreated cells (blank). After binding, 100 μl Opti-MEM were added to the washed plates, and the plates were then analyzed using a microtiter plate reader (Bio-Tek, Winooski, VT) with excitation and emission wavelengths of 485 and 528 nm, respectively.

![Figure 1 Structures of the compounds (1–8) isolated from the leaf of A. victorialis.](image-url)
Statistical analysis
Data are expressed as mean ± S.E.M. of multiple experiments. Paired Student’s t-tests were used to compare two groups, or analysis of variance with Tukey’s was used for multiple comparison tests using PRISM software (Graph Pad, San Diego, CA). Values of $p < 0.05$ were considered statistically significant.

Results and discussion
Structure elucidation of compounds
The EtOAc- and n-BuOH–soluble fractions were subjected to a series of chromatographic techniques, leading to the isolation of eight known compounds (1–8) (Figure 1). These compounds were identified as kaempferol 3,7,4′-O-β-D-triglucopyranoside (1), kaempferol 3,7,4′-O-β-D-diglucopyranoside (2), kaempferol 3,4′-O-β-D-diglucopyranoside (3), quercitrin (4), kaempferol (5), quercetin (6), 4-hydroxycinnamic acid (7), and ferulic acid (8) by comparing their physicochemical and spectral data to those in the literature [25–31].

Rat lens AR activity, AGE formation, and AGE/RAGE-binding in hRAGE-overexpressing cells
ARIs suppressing the hyperglycemia-induced polyol pathway have been identified as potential therapeutic candidates in the treatment and prevention of diabetic complications. The $IC_{50}$ values of compounds (Table 1) in this assay were comparable to that those of known ARIs, such as TMG, which suggested that the compounds and extracts appeared to have an inhibitory effect on AR activity. Among the compounds, quercitrin (4), kaempferol (5), and quercetin (6) were significantly more potent than the previously known positive control, TMG. Previous research also demonstrated that flavonoids such as quercetin and myricitrin are effective inhibitors of lens AR [28]. We previously reported that quercitrin gallate also inhibits AR activity and xylose-induced lens opacity and oxidation [25]. Kaempferol and its prenylated derivatives are reported to be aldolase inhibitor [32]. Kaempferol 3,4′-O-β-D-diglucopyranoside (3) ($IC_{50} = 9.77 ± 0.33 \mu M$) and the *A. victorialis* EtOAc- soluble fraction ($IC_{50} = 7.53 ± 0.02 \mu g/ml$) inhibited AR activity. Although, $IC_{50}$ level of EtOAc-soluble fraction was higher than TMG (0.94±0.01 μg/ml), among the extracts, it has the inhibitory effects on AGEs formation ($IC_{50} =30.13±1.68 \mu g/ml$; AG, $IC_{50} = 76.47±4.81 \mu g/ml$). Previous research indicated that genistein has inhibitory effects of AR activity in vitro, AGEs formation, and AGE-RAGE binding in hRAGE-overexpressing cells [9,23]. Next, we examined the inhibitory effects of compounds and extracts on AGEs formation (Table 1). Quercitrin (4) ($IC_{50} = 4.20 ± 0.04 \mu M$) and ferulic acid (8) ($IC_{50} = 7.50 ± 0.20 \mu M$) exhibited inhibitory effects on AGEs formation. Furthermore, because of the pronounced inhibitory effect of the three compounds (4, 5, and 6) on AR and AGEs formation, AGE-RAGE binding assays were performed in hRAGE-overexpressing cells (Figure 2). Among the compounds, quercitrin (4) significantly inhibited AGE-RAGE binding in hRAGE-overexpressing cells. Although quercitrin (4) has been tested on ARI effect [28], this compound has never been examined for the AGE-RAGE binding assay in hRAGE-overexpressing cells up to date. Quercitrin has anti-inflammatory effect through the inhibition of the NF-kappa B pathway and it shows potential anti-cancer effect, including cell cycle regulation and tyrosine kinase inhibition [33,34].

![Figure 2](http://www.biomedcentral.com/1472-6882/13/251)
Inhibition of high glucose-induced TGF-β1 expression and secretion in MMCs

TGF-β1 stimulates the production of ECM proteins such as fibronectin and collagen and promotes mesangial cell expansion [35,36]. In diabetic nephropathy, these changes are associated with the development of basement membrane thickening in the glomeruli [37]. Thus, TGF-β1 is considered a potential therapeutic target in diabetic nephropathy and other chronic renal diseases. To assess which compounds from A. victorialis are involved in the regulation of both TGF-β1 mRNA and protein levels in MMCs under diabetic conditions, cells were treated with high glucose in the presence or absence of single compounds (1–8) for 48 h. As shown in Figure 3A and B, single compounds (1–8) inhibited TGF-β1 mRNA expression in high glucose-stimulated MMCs (***p<0.001, vs. C; ###p<0.001, ##p<0.01, #p<0.05 vs. HG). Furthermore, we demonstrated that compounds from A. victorialis inhibit high glucose-induced TGF-β1 secretion (Figure 4, ***p<0.001, vs. C; ###p<0.001, ##p<0.01, #p<0.05 vs. HG). Among the eight compounds identified from A. victorialis, ferulic acid (8) displayed the greatest inhibitory effect on TGF-β1 expression in MMCs. A previous study suggested that ferulic acid have protective effects against diabetic nephropathy by reducing oxidative stress and inflammation in a rat model of type 2 diabetes [38]. In the present study, we first demonstrated that the treatment of MMCs with single compounds from A. victorialis inhibited high glucose-induced TGF-β1 mRNA expression. However, toxicology study in vivo is needed to evaluate the safety of A. victorialis in the drug development.

**Conclusion**

In summary, our data suggest that active compounds isolated from A. victorialis leaf exhibit inhibitory effects on AR activity and AGE formation. Further, ferulic acid reduces TGF-β1 mRNA expression and secretion in MMCs under diabetic conditions. Thus, the compounds isolated from A. victorialis leaf provide some scientific evidence to support the folk medicinal utilization of A. victorialis in the treatment of diabetic nephropathy. Furthermore, A. victorialis is a good candidate for the development of treatments for diabetic nephropathy.

**Competing interests**

The authors declare that they have no competing interests.

**Authors’ contributions**

YSK and JSK: Designed the study and wrote the manuscript; DHJ: Carried out the RAGE-AGE binding assay and cell culture experiments; SJC: Carried out the AGE and AR assays; ISL and SYY: Carried out the isolation of compounds; YSK and JSK: Designed the study and wrote the manuscript; ISL: Helped to draft the manuscript; SKK, MHK and JSK: Helped to discuss and supervised the work. All authors read and approved the final manuscript.

**Acknowledgements**

This research was supported by grant [K12040] from the Korea Institute of Oriental Medicine (KOM) and by grant [10039320] from the Global Leading Technology Program of the Office of Strategic R&D Planning (OSP) funded by the Ministry of Knowledge Economy, Republic of Korea. The authors would like to thank Prof. Kyu-Ryul Park, PhD; Department of Herbology, The Medical Research Division, Korea Institute of Oriental Medicine (KOM), Daejeon,
Republic of Korea. 2Development Team for the New Drug of Oriental Medicine, Daegu Haany University, Gyeongsan, Republic of Korea. 3Jeil Pharmaceutical CO., LTD, Yongsan, Kyonggi-do, Republic of Korea. *Present address: Korea Drug Development Fund, 21-1 Migeon-dong, Seodaemun-gu, Seoul 120-020, Republic of Korea.

Received: 2 July 2013 Accepted: 26 September 2013

Published: 3 October 2013

References

1. Huebschmann AG, Regensteiner JG, Vlassara H, Reusch JE: The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005, 54:1615–1625.

2. Brownlee M: The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005, 54:1615-1625.

3. Hotta N, Toyota T, Matsuoka K, Shigeta Y, Kikkawa R, Kaneko T, Takahashi A, Sugimura K, Koye Y, Ishi J, Sakamoto N: Clinical efficacy of fiaidestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52-week multicenter placebo-controlled double-blind parallel group study. Diabetes Care 2001, 24:1776–1782.

4. Kinoshita JH, Dvornik D, Kraml M, Gabbay KH: The effect of an aldose reductase inhibitor on diabetic rats. Biochim Biophys Acta 1988, 958:422–450.

5. Obrosova IG, Mirchenko AG, Vasupuram R, White L, Abatan OI, Kumagai AK, Frank RN, Stevens MJ: Aldose reductase inhibitor fiaidestat prevents retinal oxidative stress and vascular endothelial growth factor overexpression in streptozotocin-diabetic rats. Diabetes 2003, 52:864–871.

6. Itagaki I, Shimizu K, Kamaranka Y, Etaka K, Kikkawa R, Haneda M, Shigeta Y: The effect of an aldose reductase inhibitor (Epalrestat) on diabetic nephropathy in rats. Diabetes Res Clin Pract 1994, 28:147–154.

7. Jung DH, Kim YS, Kim JS: Screening system of blocking agents of the receptor for advanced glycation endproducts in cells using fluorescence. Biol Pharm Bull 2012, 35:1826–1830.

8. Dufrane SP, Malaise WJ, Sener A: A micromethod for the assay of aldose reductase, its application to pancreatic islets. Biochem Med 1984, 32:99–105.

9. Kim JS, Flavan-3-ols having a gamma-lactam from the roots of Actinidia arguta inhibit the formation of advanced glycation end products in vitro. Chem Pharm Bull (Tokyo) 2000, 48:997–1000.

10. Frank RN, Stevens MJ: Antioxidants and cancer, part 3: quercetin. J Nutr 1994, 124:691S–697S.

11. Han DC, Hoffman BB, Hong SW, Guo J, Ziyadeh FN: Kim YS, Kim NH, Yoo NH, Lee YM, Jeong IH, Kim JS: Quercetin gallate inhibits aldose reductase activity and xylose-induced lens opacification and oxidation. Biomed Aging Pathol 2011, 1(2):123–127.

12. Block E: Antioxidants and cancer, part 3: quercetin. J Nutr 1994, 124:691S–697S.

13. Lee KT, Choi JH, Kim DH, Son KH, Kim WB, Kwon SH, Park HJ: Constituents and the antitumor principle of Allium victorialis var. platyphyllum. Arch Pharm Res 2001, 24:44–50.

14. Shirataki Y, Motohashi N, Tani S, Sunaga K, Sakagami H, Sato K, Nakashima H, Kamamoto T, Wolford K: Antioxidative activity of Allium victorialis L. extracts **. Anticancer Res 2001, 21:3311–3319.

15. Kim TG, Kim SH, Kang SY, Jung JK, Choi DH, Park YB, Ryu JH, Han HM: Antithromogenic effect of the extract of Allium victorialis on the experimental atherosclerosis in the rabbit and transgenic mouse.,. Kor J Pharmacogn 2003, 34:119–156.

16. Lee KT, Choi JH, Kim DH, Son KH, Kim WB, Kwon SH, Park HJ: Constituents and the antitumor principle of Allium victorialis var. platyphyllum. Arch Pharm Res 2001, 24:44–50.

17. Woow K, Moon E, Park SY, Kim SY, Lee SY: Flavonoid glycosides from the leaves of Allium victorialis var. platyphyllum and their anti-neuroinflammatory effects. Bioorg Med Chem Lett 2012, 22:7465–7470.

18. Ahn YM, Lim SJ, Han HK, Choo SS: Effects of Allium vegetable intake on levels of plasma glucose, lipid and minerals in streptozotocin induced diabetic rat. Nutrition 2006, 39:433–443.

19. Kim YS, Yoo NH, Lee YM, Jeong IH, Kim JS: Quercetin gallate inhibits aldose reductase activity and xylose-induced lens opacification and oxidation. Biomed Aging Pathol 2011, 1:123–127.

20. Lee KT, Choi JH, Kim DH, Son KH, Kim WB, Kwon SH, Park HJ: Constituents and the antitumor principle of Allium victorialis var. platyphyllum. Arch Pharm Res 2001, 24:44–50.